Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 23, 2022

Discovery of TKIs That Potently and Selectively Inhibit HER2 Exon 20 Mutants While Sparing Wild-Type EGFR in NSCLC

Nature Cancer


Additional Info

Nature Cancer
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling
Nat Cancer 2022 Jul 01;3(7)821-836, B Wilding, D Scharn, D Böse, A Baum, V Santoro, P Chetta, R Schnitzer, DA Botesteanu, C Reiser, S Kornigg, P Knesl, A Hörmann, A Köferle, M Corcokovic, S Lieb, G Scholz, J Bruchhaus, M Spina, J Balla, B Peric-Simov, J Zimmer, S Mitzner, TN Fett, A Beran, L Lamarre, T Gerstberger, D Gerlach, M Bauer, A Bergner, A Schlattl, G Bader, M Treu, H Engelhardt, S Zahn, JE Fuchs, J Zuber, P Ettmayer, M Pearson, M Petronczki, N Kraut, DB McConnell, F Solca, RA Neumüller

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading